
    
      This is an interventional study of vaccination related to infection with varicella zoster
      virus. We will enroll participants of two age groups. Cohort 1 will be persons between the
      ages of 30-40; Cohort 2 will be persons who are 70 years of age or older. All participants
      will receive the FDA-approved recombinant zoster (RZV) vaccine (Shingrix) given at the
      approved dose and schedule.
    
  